Skip to main content
Bijal Shah, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

BijalDineshShahMD

Oncology • Tampa, FL

Hematologic Oncology

Physician

Request Appointment

Overview of Dr. Shah

Dr. Bijal Shah is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of South Florida Morsani College of Medicine and has been in practice 13 years. He is one of 171 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine/Pediatrics, 2004 - 2008
  • University of South Florida College of Medicine
    University of South Florida College of MedicineClass of 2004

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2008 - 2025
  • NC State Medical License
    NC State Medical License 2004 - 2008
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study
    Bijal Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Revi...
    Bijal Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience
    Bijal Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refract... 
    2019 ASCO Annual Meeting - 6/1/2019
  • A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult ... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-up of Two Pivotal Studies Including Longest Ever Follow-up of a CAR T-cell Therapy in Mantle Cell Lymphoma
    Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-up of Two Pivotal Studies Including Longest Ever Follow-up of a CAR T-cell Therapy in Mantle Cell LymphomaJune 4th, 2022
  • Kite’s Tecartus Is First CAR T Therapy Approved for Adults with B-cell ALL
    Kite’s Tecartus Is First CAR T Therapy Approved for Adults with B-cell ALLOctober 4th, 2021
  • U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
    U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaOctober 2nd, 2021
  • Join now to see all

Hospital Affiliations

Dr. Bijal Shah, Dr. Bijal Shah, MD, Dr. B Shah, Dr. Bijal Dinesh Shah